Salmonella (e.g., Salmonella Typhimurium, Etc.) Patents (Class 424/258.1)
  • Patent number: 7354592
    Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention is also directed to Salmonella sp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway gene such as the purl gene. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: April 8, 2008
    Assignees: Vion Pharmaceuticals, Inc., Yale University
    Inventors: David Bermudes, Kenneth Brooks Low
  • Patent number: 7341732
    Abstract: The present invention provides methods for treating mastitis in a milk producing animal. The methods include administering compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter.
    Type: Grant
    Filed: April 22, 2004
    Date of Patent: March 11, 2008
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Patent number: 7297338
    Abstract: There is provided a vaccine composition comprising a combination of a genetic deletion mutant S. typhimurium microorganism and a genetic deletion mutant E. coli microorganism, suitable for mass application to poultry. Also provided is a safe and effective method to protect poultry against the ravages of E. coli and Salmonella infection and disease.
    Type: Grant
    Filed: May 3, 2004
    Date of Patent: November 20, 2007
    Assignee: Wyeth
    Inventors: Henry H. Fan, Mahesh Kumar
  • Patent number: 7255851
    Abstract: Methods and compositions for detecting and localizing light originating from a mammal are disclosed. Also disclosed are methods for targeting light emission to selected regions, as well as for tracking entities within the mammal. In addition, animal models for disease states are disclosed, as are methods for localizing and tracking the progression of disease or a pathogen within the animal, and for screening putative therapeutic compounds effective to inhibit the disease or pathogen.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: August 14, 2007
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Pamela R. Contag, Christopher H. Contag, David A. Benaron
  • Patent number: 7211264
    Abstract: The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: May 1, 2007
    Assignee: Emergent Product Development UK Limited
    Inventors: Robert Graham Feldman, Gordon Dougan, Joseph David Santangelo, David William Holden, Jacqueline Elizabeth Shea, Zoe Hindle
  • Patent number: 7198774
    Abstract: Methods and compositions for detecting and localizing light originating from a mammal are disclosed. Also disclosed are methods for targeting light emission to selected regions, as well as for tracking entities within the mammal. In addition, animal models for disease states are disclosed, as are methods for localizing and tracking the progression of disease or a pathogen within the animal, and for screening putative therapeutic compounds effective to inhibit the disease or pathogen.
    Type: Grant
    Filed: June 8, 2005
    Date of Patent: April 3, 2007
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Pamela R. Contag, Christopher H. Contag, David A. Benaron
  • Patent number: 7160549
    Abstract: The present invention provides methods for making compositions including siderophore receptor polypeptides and porins from gram negative microbes. The methods include providing a gram negative microbe, disrupting the microbe, solubilizing the disrupted microbe, and isolating the polypeptides.
    Type: Grant
    Filed: April 22, 2004
    Date of Patent: January 9, 2007
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Donavan E. Zammert, Gayla K. Kallevig
  • Patent number: 7147857
    Abstract: The present invention provides methods for treating an animal having a high somatic cell count. The methods include administering compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: December 12, 2006
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Patent number: 7138125
    Abstract: The present invention provides methods for treating an animal for low milk production. The methods include administering compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter.
    Type: Grant
    Filed: April 22, 2004
    Date of Patent: November 21, 2006
    Assignee: Epitopix LLC
    Inventors: Daryll A. Emery, Darren E. Straub
  • Patent number: 7138124
    Abstract: The present invention provides compositions including at least two siderophore receptor polypeptides and at least two porins from a gram negative microbe, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of makino and methods of using such compositions.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: November 21, 2006
    Assignee: Epitopix, LLC
    Inventors: Daryll A. Emery, Darren E. Straub, Donavan E. Zammert, Gayla K. Kallevig
  • Patent number: 7132108
    Abstract: Biodegradable and biocompatible polymeric microspheres encapsulating Salmonella enteritidis are administered to chickens to provide the chickens with sustained protection against S. enteritidis infections.
    Type: Grant
    Filed: February 8, 2000
    Date of Patent: November 7, 2006
    Assignee: Agency for Science, Technology and Research
    Inventors: Yi-Yan Yang, Jimmy Kwang, Xueqin Chen, Tai-Shung Chung, Wei Liu
  • Patent number: 7115269
    Abstract: The present invention is directed to an attenuated Salmonella comprising a eukaryotic expression vector for delivery of the eukaryotic expression vector to a eukaryotic cell. Delivery may be to eukaryotic cells cultured in vitro or to cells in vivo, such as by oral administration of the attenuated Salmonella comprising the eukaryotic expression vector.
    Type: Grant
    Filed: October 18, 1999
    Date of Patent: October 3, 2006
    Assignee: Gesellschaft fuer Biotechnologische Forschung mbH (GBF)
    Inventors: Ayub Darji, Carlos A. Guzman, Kenneth Timmis, Siegfried Weiss, Birgit Gerstel, Trinad Chakraborty, Petra Wachholz, J├╝rgen Wehland
  • Patent number: 7101555
    Abstract: Mycobacterium tuberculosis protein having a molecular weight of 28 779 Da, and hybrid proteins containing at least portions of its sequence. These proteins may in particular be used in vaccines or for the detection of specific tuberculosis antibodies.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: September 5, 2006
    Assignee: Institut Pasteur
    Inventors: Anne Laqueyrerie, Gilles Marchal, Pascale Pescher, Felix Romain
  • Patent number: 7083794
    Abstract: Attenuated immunogenic bacteria having an RpoS+ phenotype, in particular, Salmonella enterica serotype Typhi having an RpoS+ phenotype and methods therefor are disclosed. The Salmonella have in addition to an RpoS+ phenotype, an inactivating mutation in one or more genes which render the microbe attenuated, and a recombinant gene capable of expressing a desired protein. The Salmonella are attenuated and have high immunogenicity so that they can be used in vaccines and as delivery vehicles for genes and gene products. Also disclosed are methods for preparing the vaccine delivery vehicles.
    Type: Grant
    Filed: May 3, 2002
    Date of Patent: August 1, 2006
    Assignee: Washington University
    Inventors: Roy Curtiss, III, Cheryl A. Nickerson
  • Patent number: 7045122
    Abstract: The present invention relates to live attenuated Salmonella strains comprising a first attenuating mutation, that are not capable of making functional RecA. The invention also relates to these bacteria for use in vaccines. Furthermore, the invention relates to vaccines based upon these bacteria, to the use of such bacteria in the manufacture of vaccines and to methods for the preparation of such vaccines.
    Type: Grant
    Filed: November 15, 2001
    Date of Patent: May 16, 2006
    Assignee: Akzo Nobel N.V.
    Inventors: Petrus Johannes Maria Nuijten, Maarten Hendrik Witvliet
  • Patent number: 7029678
    Abstract: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses.
    Type: Grant
    Filed: September 3, 2003
    Date of Patent: April 18, 2006
    Assignee: SmithKline Beecham Biologicals (S.A.)
    Inventors: Patricia Marie Momin, Nathalie Marie-Josephe Garcon
  • Patent number: 6969513
    Abstract: The present invention relates generally to a Plasmid Maintenance System for the stabilization of expression plasmids encoding foreign antigens, and methods for making and using the Plasmid Maintenance System. The invention optimizes the maintenance of expression plasmids at two dependent levels by: (1) removing sole dependence on balanced lethal maintenance functions; and (2) incorporating at least one plasmid partition function to present random segregation of expression plasmids, thereby enhancing their inheritance and stability. The Plasmid Maintenance System may be employed within a plasmid which has been recombinantly engineered to express a variety of expression products.
    Type: Grant
    Filed: January 5, 2004
    Date of Patent: November 29, 2005
    Assignee: University of Maryland, Baltimore
    Inventor: James E. Galen
  • Patent number: 6951652
    Abstract: A vaccine is disclosed which is useful for protecting a host from Gram negative infections and the effects of endotoxin, therefore preventing sepsis and septic shock. The vaccine is prepared by combining LPS free or in conjugate form with a stoichiometric excess of a peptide of the formula: (a) (A)n wherein A is Lysine or Arginine and n is an integer with a minimum value of 7; (b) (AB)m wherein A is Lysine or Arginine and B is a hydrophobic amino acid selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; m is an integer with a minimum value of 3; and (c) (ABC)p wherein A is a cationic amino acid which is Lysine or Arginine; B and C are hydrophobic amino acids which may be the same or different and are selected from the group consisting of Valine, Leucine, Isoleucine, Tyrosine, Phenylalanine and Tryptophan; p is an integer with a minimum value of 2.
    Type: Grant
    Filed: July 29, 1998
    Date of Patent: October 4, 2005
    Assignee: BioSynth S.r.l.
    Inventor: Massimo Porro
  • Patent number: 6923972
    Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Grant
    Filed: April 18, 2002
    Date of Patent: August 2, 2005
    Assignees: Vion Pharmaceuticals, Inc., Yale University
    Inventors: David Bermudes, Kenneth Brooks Low
  • Patent number: 6905691
    Abstract: The invention relates to a vaccine comprising a bacterium attenuated by a non-reverting mutation in a gene encoding a protein which promotes folding of extracytoplasmic proteins. Such mutations were initially identified as being useful in vaccines from a bank of randomly inserted, transposon mutants in which attenuation was determined as a reduction in virulence of the organism in the mouse model of infection. Site directed mutation of the gene results in a strain which shows at least 4 logs of attenuation when delivered both orally and intravenously. Animals vaccinated with such a strain are protected against subsequent challenge with the parent wild type strain. Finally, heterologous antigens such as the non-toxic and protective, binding domain from tetanus toxin, fragment C, can be delivered via the mucosal immune system using such strains of bacteria. This results in the induction of a fully protective immune response to subsequent challenge with native tetanus toxin.
    Type: Grant
    Filed: June 9, 2000
    Date of Patent: June 14, 2005
    Assignee: Celltech Pharma Europe Limited
    Inventors: Steven Neville Chatfield, Gordon Dougan, Mark Sydenham
  • Patent number: 6872547
    Abstract: The invention encompasses methods of maintaining desired recombinant genes in a genetic population of cells expressing the desired gene. The methods utilize microbial cells that have an inactivating mutation in a native essential gene encoding an enzyme which catalyzes a step in the biosynthesis of diaminopimelic acid (DAP). The cells also have an extrachromosomal vector that includes the desired gene and which is capable of homologous recombination with a chromosome of the microorganism. The vector also has a recombinant complementing gene encoding a functional replacement of the native essential gene. The cells of the invention are particularly useful for components of vaccines, including DNA vaccines.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: March 29, 2005
    Assignee: Washington University
    Inventor: Roy Curtiss, III
  • Patent number: 6863894
    Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention is also directed to Salmonella sp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway gene such as the purI gene. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: March 8, 2005
    Assignees: Vion Pharmaceuticals, Inc., Yale University
    Inventors: David Bermudes, Kenneth Brooks Low
  • Patent number: 6861247
    Abstract: Substantially pure Salmonella secreted proteins (Ssp), the sercetion of which is dependent upon the expession of PrgH; methods of diagnosing Salmonella infection; and live attenuated vaccine strains in which Ssp secretion is decreased.
    Type: Grant
    Filed: November 14, 1996
    Date of Patent: March 1, 2005
    Assignee: The General Hospital Corporation
    Inventor: Samuel I. Miller
  • Patent number: 6858211
    Abstract: This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (?3)-?-D-GalpNAc-(1?2)-?-D-PerpNAc-(1?3)-?-L-Fucp-(1?4)-?-D-Glcp-(1?), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.
    Type: Grant
    Filed: July 20, 1998
    Date of Patent: February 22, 2005
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Shousun Chen Szu, John B. Robbins, Yvonne Ageyman Konadu, Edward Konadu
  • Patent number: 6846488
    Abstract: The present invention provides methods of inducing immune responses by recombinant antigen-enterotoxin chimeric mucosal immunogens that contain the A2/B subunits of cholera toxin or heat-labile type II toxins. These chimeric immunogens differentially enhance antibody secretion, cytokine production, as well as B7-dependent co-stimulation of T cells and CD40L expression on CD4+ T cells.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: January 25, 2005
    Assignee: The UAB Research Foundation
    Inventors: Michael W. Russell, Terry D. Connell
  • Patent number: 6844423
    Abstract: The production of a purified extracellular bacterial signal called autoinducer-2 is regulated by changes in environmental conditions associated with a shift from a free-living existence to a colonizing or pathogenic existence in a host organism. Autoinducer-2 stimulates LuxQ luminescence genes, and is believed also to stimulate a variety of pathogenesis related genes in the bacterial species that produce it. A new class of bacterial genes is involved in the biosynthesis of autoinducer-2.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: January 18, 2005
    Assignees: Princeton University, University Technologies Transfer International
    Inventors: Bonnie L. Bassler, Michael G. Surette
  • Patent number: 6797275
    Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies againt S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: September 28, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Zuzana Kossaczka, Shousun Chen Szu, John B. Robbins
  • Patent number: 6783765
    Abstract: The present invention relates to a process for the preparation of a vaccine against tuberculosis and other intracellular pathogens, this vaccine is targeted against intracellular pathogens, more particularly the pathogen Mycobacterium tuberculosis and Salmonella in this case.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: August 31, 2004
    Assignee: Council of Scientific and Industrial Research
    Inventors: Javed Naim Agrewala, Naresh Sharma
  • Patent number: 6764687
    Abstract: The present invention relates to live attenuated bacteria for use as a medicament. The invention also relates to vaccines based thereon that are useful for the prevention of microbial pathogenesis. Further, the invention relates to live attenuated recombinant bacteria carrying a heterologous gene and vaccines based thereon. Finally, the invention relates to methods for the preparation of such vaccines and bacteria.
    Type: Grant
    Filed: June 9, 1999
    Date of Patent: July 20, 2004
    Assignees: Akzo Nobel N.V., Board of Governors for Higher Education, State of Rhode Island
    Inventors: Paul S. Cohen, David C. Laux, Petrus J. M. Nuijten
  • Patent number: 6756042
    Abstract: The present invention pertains to a Salmonella microorganism having an attenuating mutation which disrupts the expression of a gene located within the Spi2 pathogenicity island, and an auxotrophic mutation. The microorganism therefore has a double mutation which helps prevent reactivity of the microorganism while maintaining the effectiveness of the microorganism to elicit an immune response. The present invention also pertains to vaccine compositions and methods for treating and preventing a Salmonella infection in a patient.
    Type: Grant
    Filed: May 9, 2000
    Date of Patent: June 29, 2004
    Assignee: Microscience, Ltd.
    Inventors: Robert Graham Feldman, Gordon Dougan, Joseph David Santangelo, David William Holden, Jacqueline Elizabeth Shea, Zoe Hindle
  • Patent number: 6749831
    Abstract: Compare core LPS (lacking O-polysaccharide side chains) from Gram-negative bacteria are incorporated into a vaccine typically in liposomes. The complete core of E. coli K 12 is particularly useful. Upon administration to a mammal the vaccine stimulates synthesis of antibodies which are cross-protective against smooth and rough forms of LPS from at least two different Gram-negative bacterial strains having different core structures.
    Type: Grant
    Filed: April 25, 2000
    Date of Patent: June 15, 2004
    Assignee: Medical Defense Technology, LLC
    Inventors: Elliott Bennett-Guerrero, George Robin Barclay, Ian Raymond Poxton, Thomas James McIntosh, David Scott Snyder
  • Patent number: 6743607
    Abstract: Compositions and methods for making complex carbohydrates in a bacterial production cell are disclosed. The complex carbohydrates that can be made include oligosaccharides and polysaccharides of bacterial or mammalian origin.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: June 1, 2004
    Assignees: The Regents of the University of California, The University of Iowa Research Foundation
    Inventors: Michael A. Apicella, Bradford W. Gibson, Nancy J. Phillips
  • Patent number: 6713073
    Abstract: A method of vaccinating poultry by spraying the poultry with an effective amount of a live avirulent derivative of an enteropathogenic enterobacteria is disclosed.
    Type: Grant
    Filed: July 24, 1998
    Date of Patent: March 30, 2004
    Assignee: Megan Health, Inc.
    Inventor: Sandra M. Aehle
  • Patent number: 6680182
    Abstract: The invention provides a DNA molecule comprising a promoter sequence operably linked to a DNA sequence encoding first and second proteins linked by a hinge region wherein in that the promoter sequence can be one having activity which is induced in response to a change in the surrounding environment and the first protein can be Tetanus toxin C fragment or one or more epitopes thereof. The invention also provides intermediate molecules having a promoter operably linked to a DNA sequence encoding a first antigenic sequence and a hinge region, and at or adjacent the 3′-end thereof one or more restriction sites for the introduction of a second anti-genic sequence. In addition, the invention provides replicable expression vectors containing the DNA fusion proteins expressed therefrom, bacterial transformed with the vectors and the use of the bacteria, in vaccines.
    Type: Grant
    Filed: July 21, 1995
    Date of Patent: January 20, 2004
    Assignee: Acambis Research Limited
    Inventors: Mohammed Anjam Khan, Bernardo Villarreal-Ramos, Carlos Estenio Hormaeche, Steven Neville Chatfield, Gordon Dougan
  • Publication number: 20040009191
    Abstract: Attenuated mutant Salmonella bacteria containing inactivated virulence genes are provided for use in safe, efficacious vaccines.
    Type: Application
    Filed: March 15, 2001
    Publication date: January 15, 2004
    Inventors: David E. Lowery, Michael J. Kennedy
  • Patent number: 6676945
    Abstract: Mycobacterium tuberculosis protein having a molecular weight of 28.779 Da, and hybrid proteins containing at least portions of its sequence. These proteins may in particular be used in vaccines or for the detection of specific tuberculosis antibodies.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: January 13, 2004
    Assignee: Institut Pasteur
    Inventors: Anne Laqueyrerie, Gilles Marchal, Pascale Pescher, Felix Romain
  • Patent number: 6656478
    Abstract: The present invention relates to a method of protecting pigs against disease caused by infection by heterologous serotypes of Salmonella including but not limited to S. typhimurium comprising administering to the pigs a modified live vaccine incorporating S. cholerasuis.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: December 2, 2003
    Inventors: Samuel D. Charles, Albert Surendran Abraham, Emilio Trigo-Tavera
  • Patent number: 6656479
    Abstract: The present invention provides attenuated live cultures of the pathogenic protozoan parasite, Neospora, and live vaccines against neosporosis prepared therefrom which are useful in the prevention of clinical disease and abortion in mammals.
    Type: Grant
    Filed: September 12, 2001
    Date of Patent: December 2, 2003
    Assignee: Pfizer Inc.
    Inventors: David A Brake, Byron L Blagburn, David S Lindsay
  • Publication number: 20030211122
    Abstract: Mucosal, particularly oral, microparticle conjugate vaccines against certain pathogenic microorganisms, especially intracellular pathogenic microorganisms, are disclosed. An immunizing component of such a vaccine comprises protection-generating antigens derived from a certain pathogenic microorganism, such as Mycobacterium tuberculosis or Salmonella enteritidis, conjugated, possibly via a linker, to biodegradable microparticles, particularly starch microparticles, such as cross-linked starch microparticles, e.g. polyacryl starch microparticles. Further, a method of inducing protective immunity against a certain pathogenic microorganism in a mammal, and the use of protection-generating antigens derived from a certain pathogenic microorganism conjugated, possibly via a linker to biodegradable microparticles for the production of a mucosal microparticle conjugate vaccine are described.
    Type: Application
    Filed: June 12, 2003
    Publication date: November 13, 2003
    Applicant: INNOVENTUS PROJECT AB
    Inventors: Ingvar Sjoholm, Lena Degling Wikingsson
  • Publication number: 20030180320
    Abstract: An attenuated strain of Salmonella typhimurium has been used as a vehicle for oral genetic immunization. Eukaryotic expression vectors containing the genes for b-galactosidase, or truncated forms of ActA and listeriolysin—two virulence factors of Listeria monocytogenes—that were controlled by an eukaryotic promoter have been used to transform a S. typhimurium aroA strain. Multiple or even single immunizations with these transformants induced a strong cytotoxic and helper T cell response as well as an excellent antibody response. Multiple immunizations with listeriolysin transformants protected the mice completely against a lethal challenge of L. monocytogenes. Partial protection was already observed with a single dose. ActA appeared not to be a protective antigen.
    Type: Application
    Filed: October 18, 1999
    Publication date: September 25, 2003
    Inventors: AYUB DARJI, CARLOS A. GUZMAN, KENNETH TIMMIS, SIEGFRIED WEISS, BIRGIT GERSTEL, TRINAD CHAKRABORTY, PETRA WACHHOLZ
  • Patent number: 6623739
    Abstract: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent inducers of a range of immune responses.
    Type: Grant
    Filed: February 24, 2000
    Date of Patent: September 23, 2003
    Assignee: SmithKline Beecham Biologicals s.a.
    Inventors: Patricia Marie Momin, Nathalie Marie-Josephe Garcon
  • Publication number: 20030170276
    Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Application
    Filed: April 18, 2002
    Publication date: September 11, 2003
    Applicant: Vion Pharmaceuticals, Inc.
    Inventors: David Bermudes, Kenneth Brooks Low
  • Patent number: 6613321
    Abstract: The present invention relates to live attenuated gram-negative vaccine carrier strains which are useful for expression and delivery of heterologous O-antigens (O-PS) from gram-negative pathogens. Said strains are deficient in the expression of homologous O-PS due to a defined genetic modification, preferably a deletion, and, thus, capable of efficiently expressing a desired heterologous O-PS in such a way that it is covalently coupled either to homologous or heterologous LPS core lipid A. The present invention furthermore relates to live vaccine carrier strains containing a heterologous gene or a set of heterologous genes encoding O-PS. Preferably, said strains additionally contain genes necessary for the synthesis of complete smooth heterologous LPS. The present invention also relates to live vaccines comprising said strains, preferably for immunization against gram-negative enteric pathogens.
    Type: Grant
    Filed: June 15, 1998
    Date of Patent: September 2, 2003
    Assignee: Swiss Serum and Vaccine Institute Berne
    Inventors: Didier Favre, Stanley J. Cryz, Jean-Francois Viret
  • Publication number: 20030161834
    Abstract: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.
    Type: Application
    Filed: March 3, 2003
    Publication date: August 28, 2003
    Applicant: SmithKline Beecham Biologicals s.a.
    Inventors: Martin Friede, Nathalie Garcon, Catherine Marie Ghislaine Gerard, Philippe Hermand
  • Patent number: 6605285
    Abstract: This invention relates to a process for the preparation of Salmonella vaccine by treating entrotoxin and cytotoxins with formalin and adding immuno-potentiator selected from Freund's complete adjuvant (FCA) or Vitamin E or Saponin to said concentrated toxoids to get the desired vaccine. The present invention also provides a Salmonella vaccine for protection against Salmonellosis in poultry.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: August 12, 2003
    Assignee: G.B. Pant University of Agriculture & Technology
    Inventors: Vishwashwar Dutt Sharma, Subodh Kumar, Shri Krishna Garg, Ram Sagar Mishra, Tarani Kanta Barman
  • Patent number: 6605286
    Abstract: Biologically active polypeptides and/or antigens are delivered by administering to a subject a non-invasive or non-pathogenic bacterium which expresses one or more antigens or polypeptides. The non-invasive or non-pathogenic bacterium can be included in delivery systems or pharmaceutical formulations.
    Type: Grant
    Filed: April 16, 1998
    Date of Patent: August 12, 2003
    Assignees: Vlaams Interuniversitair Instituut voor Biotechnologie, Microbial Technics Limited
    Inventors: Lothar Steidler, Erik Remaut, Jeremy Mark Wells, Richard William Falla Le Page
  • Publication number: 20030109026
    Abstract: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention is also directed to Salmonella sp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway gene such as the purI gene. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.
    Type: Application
    Filed: June 27, 2002
    Publication date: June 12, 2003
    Applicant: Vion Pharmaceuticals, Inc.
    Inventors: David Bermudes, Kenneth Brooks Low
  • Patent number: 6562349
    Abstract: It has been discovered that a vaccine comprised of fimbrin, a filamentous protein derived from the bacterial surface appendages of non-typable Haemophilus influenzae is useful in studying, preventing or reducing the severity of, otitis media. The gene sequence of the DNA coding for fimbrin and the amino acid sequence of fimbrin have also been determined. Vectors containing DNA coding for fimbrin have also been developed, and transformants have been prepared which contain such vectors and which express such DNA and provide a source of pure fimbrin.
    Type: Grant
    Filed: November 29, 1999
    Date of Patent: May 13, 2003
    Assignee: The Ohio State University Research Foundation
    Inventors: Pappachan E. Kolattukudy, Lauren O. Bakaletz, Tatiana Sirakova
  • Patent number: 6548287
    Abstract: The present invention provides gram-negative bacterial strains that produce substantially pure non-pyrogenic lipopolysaccharide or lipid A. The present invention also relates to a use of said strains for the preparation of non-pyrogenic DNA and use of the same for introducing endogenous or foreign genes into animal cells or animal tissue. Further, the present invention relates to a use of said strains for the preparation of non-pyrogenic recombinant mammalian, protozoan and viral proteins. Furthermore, the present invention relates to a use of said strains for the preparation of non-pyrogenic bacterial vaccines and vaccine vectors. Yet a further use of the present invention relates to a use of said strains for the preparation of non-pyrogenic bacterial proteins and polysaccharides antigens for use as vaccines.
    Type: Grant
    Filed: June 24, 1999
    Date of Patent: April 15, 2003
    Assignee: University of Maryland, Baltimore
    Inventors: Robert J. Powell, David M. Hone
  • Publication number: 20030068328
    Abstract: Disclosed herein methods for producing live attenuated Salmonella typhi, Salmonella paratyphi A and B and other Salmonella mutants which can be used in vaccines to prevent diseases caused by Salmonella infection. These mutants can also be used to prevent or treat diseases caused by other bacterial strains, by viral and parasitic pathogens and by tumor cells.
    Type: Application
    Filed: November 5, 2001
    Publication date: April 10, 2003
    Inventors: Ion R. Vladoianu, Jose A. Berdoz